Diabetes mellitus screening assessed in Austria

04

Oct 2019

On the 2nd of September 2019, the Austrian HTA body, the Ludwig-Boltzmann Institute (LBI-HTA) has released a report on guideline recommendations comprising screening for diabetes mellitus.

In order to identify relevant guidelines, systematic searches were conducted in four guideline databases and PubMed. In addition, a focused (Internet) hand-search was carried out. The authors included current, evidence-based guidelines on diabetes mellitus in German and English language. All recognizable recommendations referring to screening for diabetes mellitus or the corresponding screening procedures were extracted from the included guidelines. A structured synthesis of information was used to compare the contents of the recommendations from specific guidelines,.

In total, 14 relevant publications on 11 different guidelines were identified through the searches in the various sources. The included guidelines were published between 2012 and 2019 by societies in the USA and Canada (n=4), Europe (n=3), Australia (n=1), Qatar (n=2) and an international organization (n=1).

Nine of the 11 guidelines contained recommendations regarding screening for type 2 diabetes mellitus in adults. Recommendations on screening for type 1 diabetes mellitus in adults were found in 3 guidelines and on screening for diabetes mellitus in children and adolescents in 4 guidelines.

Results:

  • Screening for diabetes mellitus type 1 for adults or for children/adolescents was generally not recommended. Similarly, a population-wide screening program for diabetes mellitus type 2 was not recommended
  • For adults, a regular assessment of individual diabetes risk using validated risk assessment tools such as CANRISK or FINDRISC was recommended. Screening for type 2 diabetes mellitus using blood glucose monitoring was subsequently recommended for adults at high risk of diabetes. The guidelines consistently recommended a screening interval of 3 years
  • Screening for type 2 diabetes mellitus was recommended for children and adolescents aged 8 to 10 years or older who are overweight or obese and have at least 1 additional risk factor for type 2 diabetes mellitus. In this case, the guidelines recommended a screening interval of 2 years. Again, only blood sugar measurements were recommended as a screening test. Urine glucose tests were not mentioned in the context of screening in any of the included guidelines.

Conclusions:

  • The results of the report demonstrate that international evidence-based guidelines recommend screening for type 2 diabetes mellitus for those groups of people (adults and children/adolescents), who are at high risk for diabetes mellitus
  • A recommendation for population-wide screening for diabetes mellitus is not given
  • Overall, there are no significant inconsistencies between the guidelines regarding the recommendations on screening for diabetes mellitus. However, differences between the individual guidelines exist in the definition of high risk for diabetes mellitus.

The full report in German (with English summary) can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more